数据链接：
官方服务：
资源简介：
Chemotherapy in early-stage* TNBC patients.
应用场景：
创建时间：
2018-12-19
相关数据集
Cytochalasin D as a potential MAPK family inhibitor for treating triple-negative breast cancer
Cytochalasin D, a potent fungal metabolite, has garnered considerable attention due to its diverse biological activities and potential pharmacological applications. Renowned for its ability to disrupt
DataCite Commons2025-02-27 更新80
Cytochalasin D as a potential MAPK family inhibitor for treating triple-negative breast cancer
Cytochalasin D, a potent fungal metabolite, has garnered considerable attention due to its diverse biological activities and potential pharmacological applications. Renowned for its ability to disrupt
Taylor & Francis Group2025-02-27 更新50
List of approved drugs repurposed against TNBC.
Triple-negative breast cancer (TNBC) is an aggressive malignancy that requires effective targeted drug therapy. In this study, we employed in silico methods to evaluate the efficacy of seven approved
Figshare2023-08-14 更新20
Metadata record for the manuscript: Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: A phase II and biomarker study
Summary This metadata record provides details of the data supporting the claims of the related manuscript: “Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer:
NIAID Data Ecosystem60
Metadata record for the manuscript: OMO-1 reduces tumor progression and enhances cisplatin efficacy in a 4T1-based non c-MET addicted intraductal mouse model for triple-negative breast cancer
Summary This metadata record provides details of the data supporting the claims of the related manuscript: “OMO-1 reduces tumor progression and enhances cisplatin efficacy in a 4T1-based non c-
Figshare2021-02-18 更新50
